联环药业：公司将依加大左炔诺孕酮等特色原料药的海外推广力度

Core Viewpoint - Lianhuan Pharmaceutical (600513) is proactively addressing raw material price volatility risks by establishing a comprehensive industrial chain layout, ensuring supply chain security through its subsidiaries and production bases [1] Group 1: Company Strategy - Lianhuan Group, the controlling shareholder of Lianhuan Pharmaceutical, has developed a complete industrial chain layout with intermediate production enterprises such as Inner Mongolia Shengshi Chemical and Prin Pharmaceutical [1] - The company has established two major intermediate production bases in Inner Mongolia and Anhui to secure its supply chain [1] Group 2: Regulatory Compliance and Future Plans - The company’s predecessor, Yangzhou Pharmaceutical Factory, was one of the first in China to pass FDA on-site inspections in 1984 [1] - A new factory is set to pass FDA on-site inspection again in August 2024 [1] - The company plans to leverage its World Health Organization (WHO) pre-certification advantage to enhance the overseas promotion of specialty raw materials like Levonorgestrel, aiming to increase the export sales ratio and make the raw material business a significant growth driver [1]